Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Stay current in the industry and delve into the insights of our global teams of expert industry analysts with pharma news blogs from Pharma Intelligence. Covering an array of specialties and topics, these pharma blogs include discussion of some of the most critical subjects affecting the pharmaceuticals industry today.
91 Total results for product and free and sample content found
Citeline
It is vital to understand the role of the microbiome in immunity and vaccine response, and how the microbiome may impact the effectiveness of COVID-19 vaccine programs in the real world.
Topic Coronavirus
Datamonitor Healthcare, Pink Sheet
The FDA Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals has already led to withdrawals of four PD-1/PD-L1 inhibitor indications, with the Oncologic Drugs Advisory Committee set to review another six in late April. Over the next two years, an additional five indications may be up for review.
Topic Drug Approval Standards FDA
Trialtrove
Disruption to clinical trials was a well-documented side effect of the COVID-19 pandemic, with trial sponsors and clinical sites dramatically scaling back activities in line with increased hospital burden, lockdown measures, and reduced patient mobility.
Topic Coronavirus Clinical Trials Clinical Trials Blog BioPharmaceutical
Datamonitor Healthcare
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination.
Pharma 360
Finding and organizing critical pharmaceutical and medtech data has long been a tedious task requiring hours spent gathering information from disparate sources. Pharma360 aims to change that.
Topic Market Intelligence Outlook Medtech Combination Products Launches Platform Technologies Drug Development Landscape
Pharmaprojects
With over 63 million confirmed cases and over 1.4 million deaths worldwide as of the start of December, the COVID-19 pandemic has certainly lit a fire under the pharmaceutical industry in the pursuit of therapeutics. In the process, with the recent emergency use authorisation in the UK for Pfizer and BioNTech’s BNT-162b2 vaccine, and the 94.5% efficacy reported by Moderna for its mRNA-1273 vaccine, a new technology has shot to the forefront: the mRNA vaccine.
Datamonitor Healthcare
The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit.
Datamonitor Healthcare, Biomedtracker
Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.
Biomedtracker, Datamonitor Healthcare
With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target
Topic BioPharmaceutical Drug Review
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
